Too much of a good thing?
Ce dossier présente un ensemble d'articles concernant différents types d'immunothérapies dans le traitement des cancers (lymphocytes CAR-T, inhibiteurs de point de contrôle immunitaire ou vaccins) ainsi que le rôle du microbiome dans l'efficacité de ces traitements
As the growing wave of excitement over immunotherapies has swept through the cancer field, a concern has arisen in its wake. Are there now too many clinical trials for these novel treatments, which enlist the immune system to battle tumors? One recent tally found more than 1100 studies combining a popular new class called checkpoint inhibitor drugs, which unleash suppressed immune cells, with other treatments. Some academic researchers, pharma executives, and other experts have decried this explosion of trials as a counterproductive glut motivated more by the race for money than good science and warned that many of these efforts may not finish because of a lack of participants. Other researchers, however, think the competition is healthy—and that the best studies and combos will prevail.
Science , commentaire, 2017